Benralizumab
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Benralizumab |
| DrugBank ID | DB12023 |
| Brand Names (EU) | Fasenra |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 99.34% |
Approved Indication (EMA)
AsthmaFasenra is indicated as an add on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long acting β agonists (see section 5.1).Eosinophilic granulomatosis with polyangiitis (EGPA)Fasenra is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (see section 5.1).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | thrombocytopenia due to immune destruction | 99.34% | DL |
| 2 | dermatitis | 99.16% | DL |
| 3 | acne keloid | 99.13% | DL |
| 4 | neonatal dermatomyositis | 99.05% | DL |
| 5 | amyopathic dermatomyositis | 99.03% | DL |
| 6 | acrodermatitis chronica atrophicans | 98.92% | DL |
| 7 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | 98.90% | DL |
| 8 | hydroa vacciniforme, familial | 98.90% | DL |
| 9 | autoimmune thrombocytopenic | 98.37% | DL |
| 10 | Evans syndrome | 98.24% | DL |
| 11 | autosomal thrombocytopenia with normal platelets | 97.80% | DL |
| 12 | primary release disorder of platelets | 97.79% | DL |
| 13 | neonatal thrombocytopenia | 97.28% | DL |
| 14 | pseudo-von Willebrand disease | 97.10% | DL |
| 15 | mixed-type autoimmune hemolytic anemia | 96.78% | DL |
| 16 | drug-induced autoimmune hemolytic anemia | 96.60% | DL |
| 17 | Glanzmann thrombasthenia | 96.24% | DL |
| 18 | neonatal autoimmune hemolytic anemia | 95.90% | DL |
| 19 | proteinuria | 95.81% | DL |
| 20 | filariasis | 95.56% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.